Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    March 2017
  1. ANDL T, Zhou L, Yang K, Kadekaro AL, et al
    YAP and WWTR1: New targets for skin cancer treatment.
    Cancer Lett. 2017 Mar 7. pii: S0304-3835(17)30154.
    PubMed     Text format     Abstract available


    February 2017
  2. XU DH, Zhu Z, Xiao H, Wakefield MR, et al
    Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Cancer Lett. 2017 Feb 28. pii: S0304-3835(17)30131.
    PubMed     Text format     Abstract available


  3. GUTTERIDGE RE, Singh CK, Ndiaye MA, Ahmad N, et al
    Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Cancer Lett. 2017 Feb 22. pii: S0304-3835(17)30121.
    PubMed     Text format     Abstract available


  4. DE SOUZA LM, Robertson BM, Robertson GP
    Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings.
    Cancer Lett. 2017 Feb 2. pii: S0304-3835(17)30064.
    PubMed     Text format     Abstract available


    January 2017
  5. PEARLMAN RL, Montes de Oca MK, Pal HC, Afaq F, et al
    Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
    Cancer Lett. 2017 Jan 25. pii: S0304-3835(17)30070.
    PubMed     Text format     Abstract available


    October 2016
  6. CHOLEWA BD, Ndiaye MA, Huang W, Liu X, et al
    Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer Lett. 2016 Oct 25. pii: S0304-3835(16)30646.
    PubMed     Text format     Abstract available


  7. GOWDA R, Sharma A, Robertson GP
    Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Cancer Lett. 2016 Oct 18. pii: S0304-3835(16)30628.
    PubMed     Text format     Abstract available


    September 2016
  8. XU P, Dang Y, Wang L, Liu X, et al
    Lgr4 is crucial for skin carcinogenesis by regulating MEK/ERK and Wnt/beta-catenin signaling pathways.
    Cancer Lett. 2016 Sep 29. pii: S0304-3835(16)30547.
    PubMed     Text format     Abstract available


  9. TYAGI N, Srivastava SK, Arora S, Omar Y, et al
    Comparative analysis of the relative potential of silver, Zinc-oxide and titanium-dioxide nanoparticles against UVB-induced DNA damage for the prevention of skin carcinogenesis.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30568.
    PubMed     Text format     Abstract available


  10. LEE DG, Choi BK, Kim YH, Oh HS, et al
    The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential.
    Cancer Lett. 2016 Sep 5. pii: S0304-3835(16)30512.
    PubMed     Text format     Abstract available


    July 2016
  11. XU S, Wang H, Pan H, Shi Y, et al
    ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma.
    Cancer Lett. 2016 Jul 25. pii: S0304-3835(16)30441.
    PubMed     Text format     Abstract available


    June 2016
  12. BAPU D, Runions J, Kadhim M, Brooks SA, et al
    N-acetylgalactosamine glycans function in cancer cell adhesion to endothelial cells: A role for truncated O-glycans in metastatic mechanisms.
    Cancer Lett. 2016;375:367-74.
    PubMed     Text format     Abstract available


  13. CHEN KH, Walker AM
    Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    Cancer Lett. 2016;375:293-302.
    PubMed     Text format     Abstract available


    May 2016
  14. LU Y, Wang Y, Miao L, Haynes M, et al
    Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Cancer Lett. 2016 May 25. pii: S0304-3835(16)30338.
    PubMed     Text format     Abstract available


  15. BETTI M, Aspesi A, Biasi A, Casalone E, et al
    CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Cancer Lett. 2016 May 12. pii: S0304-3835(16)30306.
    PubMed     Text format     Abstract available


  16. NUTA O, Somaiah N, Boyle S, Chua ML, et al
    Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
    Cancer Lett. 2016;374:324-30.
    PubMed     Text format     Abstract available


    April 2016
  17. MATSUO K, Itoh T, Koyama A, Imamura R, et al
    CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma.
    Cancer Lett. 2016 Apr 28. pii: S0304-3835(16)30275.
    PubMed     Text format     Abstract available


  18. REN Y, Zhou X, Liu X, Jia HH, et al
    Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
    Cancer Lett. 2016;374:96-106.
    PubMed     Text format     Abstract available


  19. LIU B, Zhang X, Song F, Zheng H, et al
    Mir-502/SET8 regulatory circuit in pathobiology of breast cancer.
    Cancer Lett. 2016 Apr 11. pii: S0304-3835(16)30221.
    PubMed     Text format     Abstract available


  20. MA XJ, Shang L, Zhang WM, Wang MR, et al
    Mitotic regulator Nlp interacts with XPA/ERCC1 complexes and regulates nucleotide excision repair (NER) in response to UV radiation.
    Cancer Lett. 2016;373:214-21.
    PubMed     Text format     Abstract available


  21. XIAO D, Barry S, Kmetz D, Egger M, et al
    Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30211.
    PubMed     Text format     Abstract available


  22. YU C, Tang W, Wang Y, Shen Q, et al
    Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30219.
    PubMed     Text format     Abstract available


  23. WU J, Zhang S, Shan J, Hu Z, et al
    Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30218.
    PubMed     Text format     Abstract available


  24. LIANG DH, Choi DS, Ensor JE, Kaipparettu BA, et al
    The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30215.
    PubMed     Text format     Abstract available


  25. MALTONI R, Gallerani G, Fici P, Rocca A, et al
    CTCs in early breast cancer: A path worth taking.
    Cancer Lett. 2016 Apr 6. pii: S0304-3835(16)30212.
    PubMed     Text format     Abstract available


  26. MALEVA KOSTOVSKA I, Wang J, Bogdanova N, Schurmann P, et al
    Rare ATAD5 missense variants in breast and ovarian cancer patients.
    Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30209.
    PubMed     Text format     Abstract available


    March 2016
  27. LIU J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, et al
    GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30198.
    PubMed     Text format     Abstract available


  28. RIGALLI JP, Tocchetti GN, Arana MR, Villanueva SS, et al
    The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters.
    Cancer Lett. 2016 Mar 23. pii: S0304-3835(16)30200.
    PubMed     Text format     Abstract available


  29. ZHU G, Yi X, Haferkamp S, Hesbacher S, et al
    Combination with gamma-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Cancer Lett. 2016 Mar 18. pii: S0304-3835(16)30178.
    PubMed     Text format     Abstract available


  30. BRANTLEY E, Callero MA, Berardi DE, Campbell P, et al
    AhR ligand Aminoflavone inhibits alpha6-integrin expression and breast cancer sphere-initiating capacity.
    Cancer Lett. 2016 Mar 17. pii: S0304-3835(16)30175.
    PubMed     Text format     Abstract available


  31. AMPUJA M, Alarmo EL, Owens P, Havunen R, et al
    The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model.
    Cancer Lett. 2016 Mar 9. pii: S0304-3835(16)30145.
    PubMed     Text format     Abstract available


  32. GOBEL A, Thiele S, Browne AJ, Rauner M, et al
    Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2016 Mar 8. pii: S0304-3835(16)30140.
    PubMed     Text format     Abstract available


  33. LV W, Chen N, Lin Y, Ma Y, et al
    Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis.
    Cancer Lett. 2016 Mar 4. pii: S0304-3835(16)30051.
    PubMed     Text format     Abstract available


  34. ROWSON-HODEL AR, Berg AL, Wald JH, Hatakeyama J, et al
    Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
    Cancer Lett. 2016 Mar 2. pii: S0304-3835(16)30120.
    PubMed     Text format     Abstract available


  35. JACOB J, Favicchio R, Karimian N, Mehrabi M, et al
    LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.
    Cancer Lett. 2016;372:137-46.
    PubMed     Text format     Abstract available


  36. JAKHAR R, Paul S, Bhardwaj M, Kang SC, et al
    Astemizole-Histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis.
    Cancer Lett. 2016;372:89-100.
    PubMed     Text format     Abstract available


  37. XU Z, Wang Z, Jia X, Wang L, et al
    MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Cancer Lett. 2016;372:118-27.
    PubMed     Text format     Abstract available


    February 2016
  38. KIM PY, Tan O, Liu B, Trahair T, et al
    High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.
    Cancer Lett. 2016 Feb 19. pii: S0304-3835(16)30075.
    PubMed     Text format     Abstract available


  39. KAWPRASERTSRI S, Pietras RJ, Marguez-Garban DC, Boonyaratanakornkit V, et al
    Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.
    Cancer Lett. 2016 Feb 15. pii: S0304-3835(16)30068.
    PubMed     Text format     Abstract available


  40. GREK CL, Rhett JM, Bruce JS, Ghatnekar GS, et al
    Connexin 43, breast cancer tumor suppressor: missed connections?
    Cancer Lett. 2016 Feb 13. pii: S0304-3835(16)30062.
    PubMed     Text format     Abstract available


    January 2016
  41. AMOURY M, Kolberg K, Pham AT, Hristodorov D, et al
    Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Cancer Lett. 2016 Jan 21. pii: S0304-3835(16)00039.
    PubMed     Text format     Abstract available


  42. LUO M, Hou L, Li J, Shao S, et al
    VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin.
    Cancer Lett. 2016 Jan 19. pii: S0304-3835(16)00022.
    PubMed     Text format     Abstract available


  43. TANG R, Xu X, Yang W, Yu W, et al
    MED27 promotes melanoma growth by targeting AKT/MAPK and NF-kappaB/iNOS signaling pathways.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00017.
    PubMed     Text format     Abstract available


  44. SHARMA MC, Tuszynski GP, Blackman MR, Sharma M, et al
    Long-term efficacy and downstream mechanism of anti-annexina2 monoclonal antibody (anti-ANX a2 mAb) in a pre-clinical model of aggressive human breast cancer.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00025.
    PubMed     Text format     Abstract available


  45. SHARMA B, Varney ML, Saxena S, Wu L, et al
    Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
    Cancer Lett. 2016 Jan 12. pii: S0304-3835(15)00750.
    PubMed     Text format     Abstract available


  46. SUYAMA K, Onishi H, Imaizumi A, Shinkai K, et al
    CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells.
    Cancer Lett. 2016 Jan 12. pii: S0304-3835(15)00754.
    PubMed     Text format     Abstract available


    December 2015
  47. LEE DH, Jung Jung Y, Koh D, Lim Y, et al
    A synthetic chalcone, 2'-hydroxy-2,3,5'-trimethoxychalcone triggers unfolded protein response-mediated apoptosis in breast cancer cells.
    Cancer Lett. 2015 Dec 29. pii: S0304-3835(15)00768.
    PubMed     Text format     Abstract available


  48. KOUSHYAR S, Jiang WG, Dart DA
    Unveiling the potential of prohibitin in cancer.
    Cancer Lett. 2015;369:316-22.
    PubMed     Text format     Abstract available


  49. COSTANTINO VV, Lobos-Gonzalez L, Ibanez J, Fernandez D, et al
    Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis.
    Cancer Lett. 2015 Dec 21. pii: S0304-3835(15)00740.
    PubMed     Text format     Abstract available


  50. HUNG AC, Tsai CH, Hou MF, Chang WL, et al
    The synthetic beta-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
    Cancer Lett. 2015 Dec 9. pii: S0304-3835(15)00725.
    PubMed     Text format     Abstract available


  51. DE AGUIAR RB, Parise CB, Souza CR, Braggion C, et al
    Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    Cancer Lett. 2015 Dec 3. pii: S0304-3835(15)00720.
    PubMed     Text format     Abstract available


  52. STRECKER TE, Odutola SO, Lopez R, Cooper MS, et al
    The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.
    Cancer Lett. 2015;369:229-41.
    PubMed     Text format     Abstract available


    November 2015
  53. LI Z, Jiang K, Zhu X, Lin G, et al
    Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.
    Cancer Lett. 2015 Nov 14. pii: S0304-3835(15)00689.
    PubMed     Text format     Abstract available


  54. ALASMAEL N, Mohan R, Meira LB, Swales KE, et al
    Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential.
    Cancer Lett. 2015 Nov 3. pii: S0304-3835(15)00662.
    PubMed     Text format     Abstract available


  55. HE T, Qi F, Jia L, Wang S, et al
    Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p.
    Cancer Lett. 2015;368:115-25.
    PubMed     Text format     Abstract available


    October 2015
  56. ALONSO-GONZALEZ C, Gonzalez A, Martinez-Campa C, Menendez-Menendez J, et al
    Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis.
    Cancer Lett. 2015 Oct 21. pii: S0304-3835(15)00646.
    PubMed     Text format     Abstract available


    August 2015
  57. DI LAURO L, Barba M, Pizzuti L, Vici P, et al
    Androgen receptor and antiandrogen therapy in male breast cancer.
    Cancer Lett. 2015 Aug 11. pii: S0304-3835(15)00508.
    PubMed     Text format     Abstract available


  58. AMO L, Tamayo-Orbegozo E, Maruri N, Buque A, et al
    Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells.
    Cancer Lett. 2015 Aug 11. pii: S0304-3835(15)00518.
    PubMed     Text format     Abstract available


  59. CHUNG L, Phillips L, Lin MZ, Moore K, et al
    A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer.
    Cancer Lett. 2015 Aug 11. pii: S0304-3835(15)00515.
    PubMed     Text format     Abstract available


  60. MISHRA S, Srivastava AK, Suman S, Kumar V, et al
    Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer.
    Cancer Lett. 2015 Aug 11. pii: S0304-3835(15)00514.
    PubMed     Text format     Abstract available


  61. WANG C, Wang C, Wei Z, Li Y, et al
    Suppression of motor protein KIF3C expression inhibits tumor growth and metastasis in breast cancer by inhibiting TGF-beta signaling.
    Cancer Lett. 2015 Aug 10. pii: S0304-3835(15)00503.
    PubMed     Text format     Abstract available


    July 2015
  62. CAI J, Tian AX, Wang QS, Kong PZ, et al
    FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
    Cancer Lett. 2015 Jul 22. pii: S0304-3835(15)00435.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: